Published in Mol Ther on March 04, 2014
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Mol Ther (2017) 0.82
Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81
How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity? Front Oncol (2014) 0.80
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic Virother (2016) 0.77
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Sequences of the major antibody binding epitopes of the Indiana serotype of vesicular stomatitis virus. Virology (1986) 2.29
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med (1995) 1.96
Purification of melanoma growth stimulatory activity. J Cell Physiol (1986) 1.73
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res (2002) 1.72
Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol (2008) 1.72
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res (1998) 1.72
Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus. J Immunol (1986) 1.64
Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol (1998) 1.62
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
The role of somatic mutation in the generation of the protective humoral immune response against vesicular stomatitis virus. Immunity (1996) 1.45
CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol (2008) 1.30
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules. Virology (1997) 1.25
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 1.22
The CD1 system. Tissue Antigens (1991) 1.16
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 1.16
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2010) 1.15
Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther (2003) 1.09
The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology (1987) 1.06
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther (2012) 1.03
Vesicular stomatitis virus matrix protein impairs CD1d-mediated antigen presentation through activation of the p38 MAPK pathway. J Virol (2008) 0.99
Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res (2001) 0.98
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med (2005) 0.97
CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells. Br J Cancer (2010) 0.96
Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther (2010) 0.91
MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia. J Exp Med (2013) 0.89
Endosomal/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus. Virology (1999) 0.88
Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J Urol (2010) 0.87
Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol (2011) 0.87
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol (2011) 0.84
Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling. Gene Ther (2011) 0.84
[Vesicular stomatitis virus in the fight against cancer]. Med Sci (Paris) (2013) 0.80
A molecular profile of T-cell exhaustion in cancer. Oncoimmunology (2012) 0.79
Orf virus interferes with MHC class I surface expression by targeting vesicular transport and Golgi. BMC Vet Res (2012) 0.77